HUA MEDICINE-B

Hua Medicine closed up 9.83% at HKD 2.57 today, driven by the expanded partnership with DKSH for the Hong Kong rollout of its diabetes drug Huatangning and a rebound from recent oversold levels. The stock opened 1.7% higher and surged to an intraday high of HKD 2.62 before paring gains, with a full-day range of 6.98%. Operationally, the company's Q4 2025 revenue surged 87.94% YoY to HKD 153.2 million, while net loss narrowed 24.83%, underscoring improving fundamentals. However, the stock remains 48.08% below its 52-week high of HKD 4.95 and below the 60-day moving average of HKD 2.994, suggesting the price recovery is still in its early stages.

华领医药今日低开高走，上午盘一度冲高至 2.440 港元后回落，下午盘重拾升势收于 2.370 港元，较前收 2.120 港元大涨 11.8%。主因是公司与大昌华嘉扩大合作支持香港糖尿病药物华堂宁上市的消息提振，叠加市场对近期香港获批上市及 ADA 2026 展示 Dorzagliatin 代谢疾病潜力的乐观情绪延续。基本面上，公司 Q4 2025 营收同比增长 87.94% 至 1.53 亿港元，净亏损同比收窄 24.83%，但净利率仍为-28.16%，显示商业化初期的盈利压力。目前股价较 52 周高点 4.95 港元折让 52.12%，同时站上 20 日均线 2.232 港元，反映短期动能改善但中期仍低于 60 日均线 3.012 港元，YTD 跌幅 22.3%。